Skip to main content
. 2024 May 9;15:55–67. doi: 10.2147/LCTT.S455034

Figure 5.

Figure 5

Anti-tumor efficacy of PD-L1 mAb in combination with selinexor and trametinib in vivo. (A) Time schedule for the LLC subcutaneous implantation and drug treatment groups, mice were randomly grouped into 7 groups: Model group, Vehicle + Isotype group, selinexor + Isotype group, trametinib + Isotype group, PD-L1 mAb + Vehicle group, selinexor + PD-L1 mAb group, and selinexor + PD-L1 mAb + trametinib group. (B) Tumor volumes for subcutaneous LLC tumor. (C) Mice body weight in each group. (D) Subcutaneous tumor weight in each group. (E) Representative LLC tumor pictures. (n=5). Data were analyzed using one-way ANOVA comparisons. *P <0.05, compared to the selinexor + Isotype group. (Regarding the results in (B and D)), there is a certain measurement error in measuring the size of a subcutaneous tumor with caliper (B). In fact, the smaller the tumor, the greater the measurement error. The actual tumor weight (D) and pictures (C) excised from mice are more accurate and intuitive.